Advertisement

Hormones and Cancer

, Volume 9, Issue 1, pp 55–61 | Cite as

Statin Use and Breast Cancer Prognosis in Black and White Women

  • Amanda LeiterEmail author
  • Nina A. Bickell
  • Derek LeRoith
  • Anupma Nayak
  • Sheldon M. Feldman
  • Neil B. Friedman
  • Alison Estabrook
  • Tari A. King
  • Kezhen Fei
  • Rebeca Franco
  • Emily J. Gallagher
Original Paper
  • 183 Downloads

Abstract

Studies show decreased risk of breast cancer recurrence and improved survival with statin use, but data on racial disparities regarding breast cancer prognosis and statin use are lacking. Our objective was to investigate if racial disparities in breast cancer prognosis can be partially explained by differences in pre-diagnosis statin use. Patients were identified from a prospective, multicenter study examining the effects of metabolic factors on breast cancer prognosis in Black and White women. Statin use, prognosis (as measured by Nottingham Prognostic Index), anthropometric, tumor, and socio-demographic characteristics were examined. Five hundred eighty-seven women (487 White, 100 Black) with newly diagnosed primary invasive breast cancer were recruited. Obesity was more prevalent in Black women than White women (47 vs 19%, p < 0.01); both groups had similar low-density lipoprotein (LDL) cholesterol levels (113 ± 41 vs 113 ± 36 mg/dl, p = 0.90). More Black women used statins than White women (18 vs 11%, p = 0.06). Black women had a worse prognosis in an adjusted model than White women (OR 2.13 95% CI 1.23–3.67). Statin use was not associated with prognosis in unadjusted (OR 1.03, 95% CI 0.53–2.0) and adjusted models (OR 1.14, 95% CI 0.56–2.31). In women with newly diagnosed breast cancer, Black women were more likely to be treated with statins than White women, contrary to previous studies. Black women had worse prognosis than White women, but this difference was not explained by differences in pre-diagnosis statin use. Our study suggests that differences in pre-diagnosis statin use do not contribute to racial disparities in breast cancer prognosis.

Notes

Author Contributions

Conception and design: A. Leiter, N.A. Bickell, D. Leroith, K. Fei, R. Franco, E.J. Gallagher

Development of methodology: A. Leiter, N.A. Bickell, D. Leroith, K. Fei, E.J. Gallagher

Acquisition of data: N.A. Bickell, A. Nayak, S. Feldman, N.B. Friedman, A. Estabrook, T.A. King

Analysis and interpretation of data: K. Fei, A. Leiter, N.A. Bickell, D. Leroith, E.J. Gallagher

Writing, review, and/or revision of the manuscript: A. Leiter, N.A. Bickell, D. Leroith, A. Nayak, S. Feldman, N.B. Friedman, T.A King, K. Fei, R. Franco, E.J. Gallagher

Administrative, technical, or material support: R. Franco

Funding Information

This work was supported by the National Cancer Institute (NCI) grant 1R01CA171558-01 (authors NAB and DL), NCI grant K08CA190779, and Tisch Cancer Institute Young Scientist Cancer Research Award, as funded by the JJR Foundation (author EJG).

Compliance with Ethical Standards

Conflict of Interest

The authors declare that there are no conflicts of interest.

References

  1. 1.
    Hunt BR, Whitman S, Hurlbert MS (2014) Increasing Black:White disparities in breast cancer mortality in the 50 largest cities in the United States. Cancer Epidemiol 38(2):118–123.  https://doi.org/10.1016/j.canep.2013.09.009 CrossRefPubMedGoogle Scholar
  2. 2.
    Iqbal J, Ginsburg O, Rochon PA, Sun P, Narod SA (2015) Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA 313(2):165–173.  https://doi.org/10.1001/jama.2014.17322 CrossRefPubMedGoogle Scholar
  3. 3.
    Liu J, Coady S, Carr JJ, Hoffmann U, Taylor HA, Fox CS (2014) Differential associations of abdominal visceral, subcutaneous adipose tissue with cardiometabolic risk factors between African and European Americans. Obesity (Silver Spring) 22(3):811–818.  https://doi.org/10.1002/oby.20307 CrossRefGoogle Scholar
  4. 4.
    Frank AT, Zhao B, Jose PO, Azar KM, Fortmann SP, Palaniappan LP (2014) Racial/ethnic differences in dyslipidemia patterns. Circulation 129(5):570–579.  https://doi.org/10.1161/circulationaha.113.005757 CrossRefPubMedGoogle Scholar
  5. 5.
    Mainous AG 3rd, Wells BJ, Koopman RJ, Everett CJ, Gill JM (2005) Iron, lipids, and risk of cancer in the Framingham Offspring cohort. Am J Epidemiol 161(12):1115–1122.  https://doi.org/10.1093/aje/kwi131 CrossRefPubMedGoogle Scholar
  6. 6.
    Gu Q, Paulose-Ram R, Burt VL, Kit BK (2014) Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003-2012. NCHS Data Brief 177:1–8Google Scholar
  7. 7.
    Ghosh-Choudhury N, Mandal CC, Ghosh-Choudhury N, Ghosh Choudhury G (2010) Simvastatin induces depression of PTEN expression via NFkappaB to inhibit breast cancer cell growth. Cell Signal 22(5):749–758.  https://doi.org/10.1016/j.cellsig.2009.12.010 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Campbell MJ, Esserman LJ, Zhou Y, Shoemaker M, Lobo M, Borman E, Baehner F, Kumar AS, Adduci K, Marx C, Petricoin EF, Liotta LA, Winters M, Benz S, Benz CC (2006) Breast cancer growth prevention by statins. Cancer Res 66(17):8707–8714.  https://doi.org/10.1158/0008-5472.can-05-4061 CrossRefPubMedGoogle Scholar
  9. 9.
    Park YH, Jung HH, Ahn JS, Im YH (2013) Statin induces inhibition of triple negative breast cancer (TNBC) cells via PI3K pathway. Biochem Biophys Res Commun 439(2):275–279.  https://doi.org/10.1016/j.bbrc.2013.08.043 CrossRefPubMedGoogle Scholar
  10. 10.
    Kwan ML, Habel LA, Flick ED, Quesenberry CP, Caan B (2008) Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Res Treat 109(3):573–579.  https://doi.org/10.1007/s10549-007-9683-8 CrossRefPubMedGoogle Scholar
  11. 11.
    Ahern TP, Pedersen L, Tarp M, Cronin-Fenton DP, Garne JP, Silliman RA, Sorensen HT, Lash TL (2011) Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. J Natl Cancer Inst 103(19):1461–1468.  https://doi.org/10.1093/jnci/djr291 CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Chae YK, Valsecchi ME, Kim J, Bianchi AL, Khemasuwan D, Desai A, Tester W (2011) Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and/or statins. Cancer Investig 29(9):585–593.  https://doi.org/10.3109/07357907.2011.616252 CrossRefGoogle Scholar
  13. 13.
    Nickels S, Vrieling A, Seibold P, Heinz J, Obi N, Flesch-Janys D, Chang-Claude J (2013) Mortality and recurrence risk in relation to the use of lipid-lowering drugs in a prospective breast cancer patient cohort. PLoS One 8(9):e75088.  https://doi.org/10.1371/journal.pone.0075088 CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Boudreau DM, Yu O, Chubak J, Wirtz HS, Bowles EJ, Fujii M, Buist DS (2014) Comparative safety of cardiovascular medication use and breast cancer outcomes among women with early stage breast cancer. Breast Cancer Res Treat 144(2):405–416.  https://doi.org/10.1007/s10549-014-2870-5 CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Murtola TJ, Visvanathan K, Artama M, Vainio H, Pukkala E (2014) Statin use and breast cancer survival: a nationwide cohort study from Finland. PLoS One 9(10):e110231.  https://doi.org/10.1371/journal.pone.0110231 CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Cardwell CR, Hicks BM, Hughes C, Murray LJ (2015) Statin use after diagnosis of breast cancer and survival: a population-based cohort study. Epidemiology 26(1):68–78.  https://doi.org/10.1097/ede.0000000000000189 CrossRefPubMedGoogle Scholar
  17. 17.
    Brewer TM, Masuda H, Liu DD, Shen Y, Liu P, Iwamoto T, Kai K, Barnett CM, Woodward WA, Reuben JM, Yang P, Hortobagyi GN, Ueno NT (2013) Statin use in primary inflammatory breast cancer: a cohort study. Br J Cancer 109(2):318–324.  https://doi.org/10.1038/bjc.2013.342 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Desai P, Lehman A, Chlebowski RT, Kwan ML, Arun M, Manson JE, Lavasani S, Wasswertheil-Smoller S, Sarto GE, LeBoff M, Cauley J, Cote M, Beebe-Dimmer J, Jay A, Simon MS (2015) Statins and breast cancer stage and mortality in the Women’s Health Initiative. Cancer Causes Control: CCC 26(4):529–539.  https://doi.org/10.1007/s10552-015-0530-7 CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Mc Menamin UC, Murray LJ, Hughes CM, Cardwell CR (2016) Statin use and breast cancer survival: a nationwide cohort study in Scotland. BMC Cancer 16:600.  https://doi.org/10.1186/s12885-016-2651-0 CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Smith A, Murphy L, Sharp L, O'Connor D, Gallagher WM, Bennett K, Barron TI (2016) De novo post-diagnosis statin use, breast cancer-specific and overall mortality in women with stage I-III breast cancer. Br J Cancer 115(5):592–598.  https://doi.org/10.1038/bjc.2016.232 CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Johansen ME, Hefner JL, Foraker RE (2015) Antiplatelet and statin use in US patients with coronary artery disease categorized by race/ethnicity and gender, 2003 to 2012. Am J Cardiol 115(11):1507–1512.  https://doi.org/10.1016/j.amjcard.2015.02.052 CrossRefPubMedGoogle Scholar
  22. 22.
    Lipworth L, Fazio S, Kabagambe EK, Munro HM, Nwazue VC, Tarone RE, McLaughlin JK, Blot WJ, Sampson UK (2014) A prospective study of statin use and mortality among 67,385 blacks and whites in the Southeastern United States. Clin Epidemiol 6:15–25.  https://doi.org/10.2147/clep.s53492 PubMedGoogle Scholar
  23. 23.
    Mercado C, DeSimone AK, Odom E, Gillespie C, Ayala C, Loustalot F (2015) Prevalence of cholesterol treatment eligibility and medication use among adults—United States, 2005–2012. MMWR Morb Mortal Wkly Rep 64(47):1305–1311.  https://doi.org/10.15585/mmwr.mm6447a1 CrossRefPubMedGoogle Scholar
  24. 24.
    Lewey J, Shrank WH, Bowry AD, Kilabuk E, Brennan TA, Choudhry NK (2013) Gender and racial disparities in adherence to statin therapy: a meta-analysis. Am Heart J 165(5):665–678, 678.e661.  https://doi.org/10.1016/j.ahj.2013.02.011 CrossRefPubMedGoogle Scholar
  25. 25.
    Gallagher EJ, LeRoith D, Franco R, Antoniou IM, Nayak A, Livaudais-Toman J, Bickell N (2016) Metabolic syndrome and pre-diabetes contribute to racial disparities in breast cancer outcomes: hypothesis and proposed pathways. Diabetes Metab Res Rev.  https://doi.org/10.1002/dmrr.2795
  26. 26.
    Elewonibi B, Miranda PY (2017) Using mammograms to predict preventive health services behavior and mortality in women. Prev Med Rep 5:27–32.  https://doi.org/10.1016/j.pmedr.2016.10.012 CrossRefPubMedGoogle Scholar
  27. 27.
    Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383CrossRefPubMedGoogle Scholar
  28. 28.
    Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Fernando C (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement: executive summary. Crit Pathw Cardiol 4(4):198–203CrossRefPubMedGoogle Scholar
  29. 29.
    Balslev I, Axelsson CK, Zedeler K, Rasmussen BB, Carstensen B, Mouridsen HT (1994) The Nottingham Prognostic Index applied to 9,149 patients from the studies of the Danish Breast Cancer Cooperative group (DBCG). Breast Cancer Res Treat 32(3):281–290CrossRefPubMedGoogle Scholar
  30. 30.
    Bates T, Evans T, Lagord C, Monypenny I, Kearins O, Lawrence G (2014) A population based study of variations in operation rates for breast cancer, of comorbidity and prognosis at diagnosis: failure to operate for early breast cancer in older women. Eur J Surg Oncol 40(10):1230–1236.  https://doi.org/10.1016/j.ejso.2014.06.001 CrossRefPubMedGoogle Scholar
  31. 31.
    Albergaria A, Ricardo S, Milanezi F, Carneiro V, Amendoeira I, Vieira D, Cameselle-Teijeiro J, Schmitt F (2011) Nottingham Prognostic Index in triple-negative breast cancer: a reliable prognostic tool? BMC Cancer 11:299.  https://doi.org/10.1186/1471-2407-11-299 CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Parisi F, Gonzalez AM, Nadler Y, Camp RL, Rimm DL, Kluger HM, Kluger Y (2010) Benefits of biomarker selection and clinico-pathological covariate inclusion in breast cancer prognostic models. Breast Cancer Res: BCR 12(5):R66.  https://doi.org/10.1186/bcr2633 CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report (2002) Circulation 106(25):3143–3421Google Scholar
  34. 34.
    Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW, Eddleman KM, Jarrett NM, LaBresh K, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli GF (2014) 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129(25 Suppl 2):S1–45.  https://doi.org/10.1161/01.cir.0000437738.63853.7a CrossRefPubMedGoogle Scholar
  35. 35.
    Chen L, Li CI (2015) Racial disparities in breast cancer diagnosis and treatment by hormone receptor and HER2 status. Cancer Epidemiol Biomark Prev 24(11):1666–1672.  https://doi.org/10.1158/1055-9965.epi-15-0293 CrossRefGoogle Scholar
  36. 36.
    Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348(17):1625–1638.  https://doi.org/10.1056/NEJMoa021423 CrossRefPubMedGoogle Scholar
  37. 37.
    Silber JH, Rosenbaum PR, Clark AS, Giantonio BJ, Ross RN, Teng Y, Wang M, Niknam BA, Ludwig JM, Wang W, Even-Shoshan O, Fox KR (2013) Characteristics associated with differences in survival among black and white women with breast cancer. JAMA 310(4):389–397.  https://doi.org/10.1001/jama.2013.8272 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  • Amanda Leiter
    • 1
    Email author
  • Nina A. Bickell
    • 1
    • 2
  • Derek LeRoith
    • 3
  • Anupma Nayak
    • 4
  • Sheldon M. Feldman
    • 5
  • Neil B. Friedman
    • 6
  • Alison Estabrook
    • 7
  • Tari A. King
    • 8
  • Kezhen Fei
    • 2
  • Rebeca Franco
    • 2
  • Emily J. Gallagher
    • 3
  1. 1.Department of MedicineIcahn School of Medicine at Mount SinaiNew YorkUSA
  2. 2.Department of Population Health Sciences and Policy, Center for Health Equity & Community Engaged ResearchIcahn School of Medicine at Mount SinaiNew YorkUSA
  3. 3.Division of Endocrinology, Diabetes and Bone Diseases, Department of MedicineIcahn School of Medicine at Mount SinaiNew YorkUSA
  4. 4.Department of PathologyIcahn School of Medicine at Mount SinaiNew YorkUSA
  5. 5.Department of SurgeryColumbia University Medical CenterNew YorkUSA
  6. 6.Department of SurgeryMercy Medical CenterBaltimoreUSA
  7. 7.Department of Surgery, Mount Sinai WestIcahn School of Medicine at Mount SinaiNew YorkUSA
  8. 8.Department of SurgeryMemorial Sloan Kettering Cancer CenterNew YorkUSA

Personalised recommendations